背景:制药公司和医生之间的财务互动导致利益冲突。这项研究调查了2016年至2020年间日本制药公司向董事会认证的过敏症患者支付的非研究费用的程度和趋势。
方法:对日本药品制造商协会下属制药公司披露的支付数据进行了回顾性分析。这项研究的重点是讲座的非研究费用,咨询,以及2016年至2020年向董事会认证的变态反应学家起草的手稿。我们对付款数据进行了描述性分析。使用广义估计方程模型对趋势进行了分析。
结果:在3,943名经董事会认证的过敏症专科医生中,2,398(60.8%)在五年内获得了总计4,340万美元的非研究付款。演讲费占付款总额的85.7%(3720万美元)。对于至少收到一笔付款的过敏症患者,每位过敏症患者的中位数为3,106美元(四分位数范围:966-12,124美元),相比之下,五年期间的平均值为18092美元(标准偏差:49233美元)。这些过敏症患者中排名前1%和10%的患者占所有非研究费用的20.8%和68.8%,分别。年度付款金额大幅增加7.2%(95%CI:4.4-10.0%,p<0.001),直到2019年,但在COVID-19大流行期间,2020年出现显著下降。
结论:大多数过敏症患者获得了非研究费用,在一小群人中有明显的浓度。在大流行爆发之前,付款每年都在增加,这与大幅下降相吻合。需要进一步的研究来探索这些财务互动对日本临床实践和患者护理的影响。
Financial interactions between pharmaceutical companies and physicians lead to conflicts of interest. This study examines the extent and trends of non-research payments made by pharmaceutical companies to board-certified allergists in Japan between 2016 and 2020.
A retrospective analysis of disclosed payment data from pharmaceutical companies affiliated with the Japanese Pharmaceutical Manufacturers Association was conducted. The study focused on non-research payments for lecturing, consulting, and manuscript drafting made to board-certified allergists from 2016 to 2020. We performed descriptive analyses on payment data. Trends were analyzed using generalized estimating equation models.
Of the 3,943 board-certified allergists, 2,398 (60.8%) received non-research payments totaling $43.4 million over five years. Lecturing fees comprised 85.7% ($37.2 million) of the total payment amounts. For allergists who received at least one payment, the median amount per allergist was $3,106 (interquartile range: $966 - $12,124), in contrast to a mean of $18,092 (standard deviation: $49,233) over the five-year span. The top 1% and 10% of these allergists accounted for 20.8% and 68.8% of all non-research payments, respectively. The annual payment amounts significantly increased by 7.2% annual increase (95% CI: 4.4 - 10.0%, p < 0.001) each year until 2019, but saw a significant decrease in 2020 amid the COVID-19 pandemic.
The majority of allergists received non-research payments, with a notable concentration among a small group. Payments increased annually until the pandemic\'s onset, which coincided with a substantial decrease. Further research is needed to explore the implications of these financial interactions on clinical practice and patient care in Japan.